PD166793 hydrate
SIGMA/P0047 - ≥98% (HPLC)
Synonym: (S)-2-(4′-Bromo-biphenyl-4-sulfonylamino)-3-methyl-butyric acid hydrate
CAS Number: 1228078-64-5
Empirical Formula (Hill Notation): C17H18BrNO4S · xH2O
Molecular Weight: 412.30 (anhydrous basis)
MDL Number: MFCD12912437
Linear Formula: C17H18BrNO4S · xH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| form | solid |
| InChI | 1S/C17H18BrNO4S.H2O/c1-11 |
| InChI key | LUKRECOTGXWIDO-NTISSMGPSA |
| Quality Level | 100  |
| SMILES string | O.CC(C)[C@H](NS(=O)(=O)c1 |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | PD166793 is a broad spectrum, but class-selective, MMP inhibitor (low nM at MMP-2 & 3 and low μM at MMP-1, 7 & 9). |
| Biochem/physiol Actions: | PD166793 is a broad spectrum, but class-selective, MMP inhibitor (low nM at MMP-2 & 3 and low μM at MMP-1, 7 & 9). Adding PD166793 to the high-fat diet substantially reduced the rise in blood glucose. The improvement of glucose homeostasis in PD166793-treated ZDF rats was a result of the enhancement of β-cell function. It prevents β-cell dysfunction and diabetes in female ZDF rats on a high-fat diet. It has been shown to block left ventricular remodeling and dysfunction in a rat model of heart failure. Preservation of normoglycemia and normal glucose tolerance in compound PD166793-treated animals is accompanied by preservation of the high serum insulin levels that are a consequence of the insulin resistance present in these animals. It is not reversing insulin resistance these animals. The most striking effect of the compound is on pancreatic insulin content and β-cell volume. |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |